SynthesisEuropean journal of clinical pharmacology2026
Efficacy and safety of vericiguat across the spectrum of heart failure: a systematic review and updated meta‑analysis of randomized controlled trials.
Synthesis in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond the Four Pillars: A Risk-Targeted Framework for Vericiguat-A Narrative Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) remains a major global burden. Vericiguat, a soluble guanylate cyclase stimulator, has been tested across HF phenotypes. Given mixed trial results, an updated synthesis is needed to clarify its role in HFrEF and HFpEF.
methodsWe systematically searched three databases for RCTs comparing vericiguat with placebo in heart failure. Endpoints included cardiovascular death, heart failure hospitalization, their composite, all-cause death, and safety events. Pooled hazard ratios (HR) and risk ratios (RR) with 95% confidence intervals (CI) were calculated using random-effects models.
resultsFive RCTs (12,877 patients) met the inclusion criteria. In HFrEF, vericiguat reduced the composite of cardiovascular death or heart failure hospitalization (Three RCTs, 11,520 patients; HR 0.91; 95% CI 0.85–0.97) and achieved a significant reduction in cardiovascular death (Two RCTs, 11,155 patients; HR 0.88; 95% CI 0.79–0.99). Effects on all-cause death were not significant in HFrEF (Two RCTs, 11,155 patients; HR 0.90; 95% CI 0.80–1.01). Across HFpEF trials, which were short-duration and not powered for hard outcomes, effects were neutral, reflecting insufficient evidence rather than a definitive lack of benefit. In the overall population, safety analyses showed no increase in serious adverse events (Five RCTs, 12,850 patients; RR 0.95; 95% CI 0.89–1.00). Symptomatic hypotension was more frequent (Five RCTs, 12,850 patients; RR 1.20; 95% CI 1.07–1.34), consistent with the drug’s hemodynamic effects, whereas rates of syncope were unchanged.
conclusionVericiguat provides a modest but consistent reduction in cardiovascular death or HF hospitalization in HFrEF, with no effect on all-cause death. Evidence in HFpEF remains inconclusive due to limited trial duration and event rates. Safety is acceptable, with hypotension as the main adverse effect. These results support its use as an adjunct in selected HFrEF patients.
Indexed as
Identifiers
41843131What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.